Deal signed less than a month before the planned launch of the opioid-induced constipation (OIC) treatment for adults with chronic non-cancer pain.
A new HIV drug reduced viral replication and increased immune cells in individuals with advanced, drug-resistant HIV infection.
Pergamum agreed to collaborate with Cadila Pharmaceuticals to develop a new treatment for infections based on a novel targeting mechanism that is different from classical antibiotic therapy.
A rationally designed drug-like protein interferes with the protein-protein interactions of PCNA, the so-called DNA clamp, offering a new way of hindering DNA replication in fast-proliferating cancer cells.
New technology incorporates a range of useful non-canonical amino acids into proteins made in eukaryotes.
Novel platform for antibiotic discovery looks to overcome problem of antibiotic resistance
Please wait while you are redirected to the right page...